138 related articles for article (PubMed ID: 32653380)
1. Protein-metallodrugs interactions: Effects on the overall protein structure and characterization of Au, Ru and Pt binding sites.
Loreto D; Ferraro G; Merlino A
Int J Biol Macromol; 2020 Nov; 163():970-976. PubMed ID: 32653380
[TBL] [Abstract][Full Text] [Related]
2. Photophysical properties of ruthenium(II) polypyridyl-gold(I) ethynyl dyads and triads containing mono- or diethynylphenanthroline incorporated into gold(I) triphenylphosphine organometallics.
Shiotsuka M; Tsuji Y; Keyaki K; Nozaki K
Inorg Chem; 2010 May; 49(9):4186-93. PubMed ID: 20364844
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in protein metalation: structural studies.
Merlino A
Chem Commun (Camb); 2021 Feb; 57(11):1295-1307. PubMed ID: 33464256
[TBL] [Abstract][Full Text] [Related]
4. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
5. Metal-metal interactions in platinum(II)/gold(I) or platinum(II)/silver(I) salts containing planar cations and linear anions.
Stork JR; Rios D; Pham D; Bicocca V; Olmstead MM; Balch AL
Inorg Chem; 2005 May; 44(10):3466-72. PubMed ID: 15877427
[TBL] [Abstract][Full Text] [Related]
6. Caged noble metals: Encapsulation of a cytotoxic platinum(II)-gold(I) compound within the ferritin nanocage.
Ferraro G; Petruk G; Maiore L; Pane F; Amoresano A; Cinellu MA; Monti DM; Merlino A
Int J Biol Macromol; 2018 Aug; 115():1116-1121. PubMed ID: 29709536
[TBL] [Abstract][Full Text] [Related]
7. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.
Casini A; Guerri A; Gabbiani C; Messori L
J Inorg Biochem; 2008; 102(5-6):995-1006. PubMed ID: 18289690
[TBL] [Abstract][Full Text] [Related]
8. Cellular transport mechanisms of cytotoxic metallodrugs: an overview beyond cisplatin.
Spreckelmeyer S; Orvig C; Casini A
Molecules; 2014 Sep; 19(10):15584-610. PubMed ID: 25268716
[TBL] [Abstract][Full Text] [Related]
9. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
10. A novel screening method for transition metal-based anticancer compounds using zebrafish embryo-larval assay and inductively coupled plasma-mass spectrometry analysis.
Karas BF; Côrte-Real L; Doherty CL; Valente A; Cooper KR; Buckley BT
J Appl Toxicol; 2019 Aug; 39(8):1173-1180. PubMed ID: 30963621
[TBL] [Abstract][Full Text] [Related]
11. Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.
Casini A; Gabbiani C; Michelucci E; Pieraccini G; Moneti G; Dyson PJ; Messori L
J Biol Inorg Chem; 2009 Jun; 14(5):761-70. PubMed ID: 19288144
[TBL] [Abstract][Full Text] [Related]
12. Multimetallic arrays: bi-, tri-, tetra-, and hexametallic complexes based on gold(I) and gold(III) and the surface functionalization of gold nanoparticles with transition metals.
Knight ER; Leung NH; Thompson AL; Hogarth G; Wilton-Ely JD
Inorg Chem; 2009 Apr; 48(8):3866-74. PubMed ID: 19296612
[TBL] [Abstract][Full Text] [Related]
13. The mode of action of anticancer gold-based drugs: a structural perspective.
Messori L; Scaletti F; Massai L; Cinellu MA; Gabbiani C; Vergara A; Merlino A
Chem Commun (Camb); 2013 Oct; 49(86):10100-2. PubMed ID: 24045294
[TBL] [Abstract][Full Text] [Related]
14. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
[TBL] [Abstract][Full Text] [Related]
15. Principles and methods used to grow and optimize crystals of protein-metallodrug adducts, to determine metal binding sites and to assign metal ligands.
Russo Krauss I; Ferraro G; Pica A; Márquez JA; Helliwell JR; Merlino A
Metallomics; 2017 Nov; 9(11):1534-1547. PubMed ID: 28967006
[TBL] [Abstract][Full Text] [Related]
16. Direct deposition of gold nanoplates and porous platinum on substrates through solvent-free chemical reduction of metal precursors with ethylene glycol vapor.
Cho SJ; Mei X; Ouyang J
Phys Chem Chem Phys; 2012 Dec; 14(45):15793-801. PubMed ID: 23086437
[TBL] [Abstract][Full Text] [Related]
17. Photochemistry of ruthenium trisbipyridine functionalized on gold nanoparticles.
Pramod P; Sudeep PK; Thomas KG; Kamat PV
J Phys Chem B; 2006 Oct; 110(42):20737-41. PubMed ID: 17048877
[TBL] [Abstract][Full Text] [Related]
18. Interaction of Au(iii) and Pt(ii) complexes with Na/K-ATPase: experimental and theoretical study of reaction stoichiometry and binding sites.
Vujačić Nikezić AV; Janjić GV; BondŽić AM; Zarić BL; Vasić-Anićijević DD; Momić TG; Vasić VM
Metallomics; 2018 Jul; 10(7):1003-1015. PubMed ID: 29978878
[TBL] [Abstract][Full Text] [Related]
19. RNA binding and inhibition of primer extension by a Ru(III)/Pt(II) metal complex.
Jain SS; Anderson CM; DiRienzo F; Taylor IR; Jain K; Guha S; Hoque N
Chem Commun (Camb); 2013 Jun; 49(44):5031-3. PubMed ID: 23615723
[TBL] [Abstract][Full Text] [Related]
20. A ruthenium-platinum metal complex that binds to sarcin ricin loop RNA and lowers mRNA expression.
Jain SS; Anderson CM; Sapse IA; Lundgren SH; Freer AK; Hoang H; Jain K; Breshears M
Chem Commun (Camb); 2018 Aug; 54(65):8987-8990. PubMed ID: 29951655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
